重症筋無力症市場の機会の評価、疫学、臨床試験、アンメットニーズ、予測（～2032年）

当レポートでは、主要7市場における重症筋無力症について調査分析し、現在の治療オプション、アンメットニーズと機会、研究開発戦略、市場見通しなどの情報を提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 疾患の概要

• 重症筋無力症の概要
• 重症筋無力症SWOT分析
• 重症筋無力症の抗体の分類
• 重症筋無力症の分類
• 重症筋無力症のMGFA分類

第4章 疫学

• 診断されたMG患者数
• 診断されたMG患者数の動向：年齢別
• 診断されたMG患者数の動向：性別
• MG有病率の情報源と調査手法
• MGの情報源と調査手法

第5章 現在の治療オプション

• 治療パラダイム
• 現在の治療オプション
• 現在の治療オプション - KOLの視点
• 製品プロファイル：免疫抑制剤（Tacrolimus、Cyclosporine、Azathioprine）
• 製品プロファイル：コルチコステロイド（Prednisone、Hydrocortisone、Methylprednisone）
• 製品プロファイル：アセチルコリンエステラーゼ阻害薬（Pyridostigmine、Neostigmine、Ambenonium）
• 製品プロファイル：IgG阻害薬（Vyvgart, Vyvgart Hytrulo, Rystiggo）
• 製品プロファイル：補体阻害薬（Soliris、Ultomiris、Zilbrysq）
• 製品プロファイル：その他のクラス（Rituxan）

第6章 アンメットニーズと機会

• 重症筋無力症におけるアンメットニーズ
• 疾患修飾療法のコスト
• 予後バイオマーカー
• 社会と医師の意識
• 投与頻度
• 分類と治療ガイドラインの標準化

第7章 研究開発戦略

• 重症筋無力症における臨床試験設計の動向
• 重症筋無力症における研究開発戦略
• 重症筋無力症における取引の動向

第8章 パイプラインの評価

• 重症筋無力症パイプラインの概要
• 重症筋無力症に向けた後期パイプライン薬品
• 製品プロファイル：Horizon TherapeuticsのUplizna（inebilizumab）
• 製品プロファイル：RegeneronのPozelimabとAlnylamのCemdisiranの併用
• 製品プロファイル：RocheのEnspryng（satralizumab）
• 製品プロファイル：Immunovantのbatoclimab
• 製品プロファイル：Alexion/AstraZenecaのgefurulimab
• 製品プロファイル：Janssenのnipocalimab

第9章 市場見通し

• 重症筋無力症市場の予測
• 市場の促進要因と障壁

第10章 付録

第11章 連絡先

Abstract

The report provides an in-depth assessment of the Myasthenia gravis market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.

Myasthenia Gravis (MG) is an autoimmune and neuromuscular disease that is characterized by muscle weakness and fatigue. In the majority of patients, the disease is initially localized and limited to the eye muscles, causing drooping of the eyelid (ptosis) and double vision (diplopia). This weakness can give patients difficulty controlling eye and eyelid movement, facial expressions, chewing, and talking. In some cases, the disease progressively begins to affect respiratory muscles. MG is considered to be the most common neuromuscular disorder, although it is still classified as a rare disease. The precise etiology of MG is idiopathic, and while factors such as infections are known to increase susceptibility, the specific cause is often indeterminable. The disruption of the normal communication between nerves and muscles at the neuromuscular junction is a key pathological process in MG, which results in impairment of the patient's ability to engage in voluntary muscle movements.

Key Highlights

Report deliverables include a Pdf and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2022-2032

Scope

• Overview of Myasthenia gravis disease, classification of Myasthenia gravis according to the Myasthenia Gravis Foundation of America guideline, etiology, pathophysiology, and epidemiology of Myasthenia gravis
• Current treatment options including product profiles for Myasthenia gravis marketed in the 7MM.
• Analysis of unmet needs and R&A strategies within the Myasthenia gravis market.
• Pipeline analysis including product profiles for leading candidates in the 7MM.
• Myasthenia gravis market outlook including revenue breakdown by market between the years 2022 and 2032

Reasons to Buy

• Understand the trends shaping and driving the Myasthenia gravis market
• Identify the innovative technologies and key players leading the Myasthenia gravis field
• Recognize gaps and areas of unmet need within the Myasthenia gravis market
• Determine the current and future outlook for Myasthenia gravis according to key opinion leaders (KOLs)
• Track Myasthenia gravis sales from 2022-2032

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Related Reports
• 1.3. Abbreviations

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Myasthenia Gravis
• 3.2. Myasthenia Gravis SWOT Analysis
• 3.3. Antibody Classification of Myasthenia Gravis
• 3.4. Classification of Myasthenia Gravis
• 3.5. MGFA Classification of Myasthenia Gravis

4. Epidemiology

• 4.1. Diagnosed Prevalent Cases of MG
• 4.2. Age-Specific Trends in Diagnosed Prevalent Cases of MG
• 4.3. Sex-Specific Diagnosed Prevalent Cases of MG
• 4.4. Sources and Methodology for MG Prevalence
• 4.5. Sources and Methodology for MG

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Current Treatment Options
• 5.3. Current Treatment Options - KOL Perspective
• 5.4. Product Profile: Immunosuppressants (Tacrolimus, Cyclosporine, Azathioprine)
• 5.5. Product Profile: Corticosteroids (Prednisone, Hydrocortisone, Methylprednisone)
• 5.6. Product Profile: Acetylcholinesterase Inhibitors (Pyridostigmine, Neostigmine, Ambenonium)
• 5.7. Product Profile: IgG Inhibitors (Vyvgart, Vyvgart Hytrulo, Rystiggo)
• 5.8. Product Profile: Complement Inhibitors (Soliris, Ultomiris, Zilbrysq)
• 5.9. Product Profile: Other Classes (Rituxan)

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Myasthenia Gravis
• 6.2. Cost of Disease Modifying Therapies
• 6.3. Prognostic Biomarkers
• 6.4. Public and Physician Awareness
• 6.5. Frequency of Administration
• 6.6. Standardization of Classification and Treatment Guidelines

7. R&D Strategies

• 7.1. Trends in Clinical Trial Design in Myasthenia Gravis
• 7.2. R&D strategies in Myasthenia Gravis
• 7.3. Trends in Deal-Making in Myasthenia Gravis

8. Pipeline Assessment

• 8.1. Myasthenia Gravis Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Myasthenia Gravis
• 8.3. Product Profile: Horizon Therapeutic's Uplizna (inebilizumab)
• 8.4. Product Profile: Regeneron's Pozelimab in Combination with Alnylam's Cemdisiran
• 8.5. Product Profile: Roche's Enspryng (satralizumab)
• 8.6. Product Profile: Immunovant's batoclimab
• 8.7. Product Profile: Alexion's/AstraZeneca's gefurulimab
• 8.8. Product Profile: Janssen's nipocalimab

9. Market Outlook

• 9.1. Myasthenia Gravis Market Forecast
• 9.2. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research - KOL Information
• 10.2. About the Authors

11. Contact Us